This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone

This study has been completed.
Information provided by:
Peking University Identifier:
First received: December 21, 2005
Last updated: NA
Last verified: October 2004
History: No changes posted
lupus nephritis accounts for the most morbidity and mortality in patients with SLE. Glucocorticoids combined with cyclophosphamide (CYC) are effective for the treatment of patients with proliferative lupus nephritis and have been the immunosuppressive regimen of choice for many years. However, some patients do not respond well to the regimen, and adverse effects of cyclophosphamide limit its use in certain patients. Leflunomide is a novel immunosuppressive agent currently used in the treatment of rheumatoid arthritis.There were a few pilot observational studies and reports suggesting leflunomide was also safe, well-tolerated and may be effective in SLE patients without important organ involvement. It has not been shown if leflunomide can be used in the treatment of patients with lupus nephritis. We therefore undertook a multi-center, controlled study to investigate the efficacy and safety profile of leflunomide compared with cyclophosphamide in the treatment of patients with biopsy proven proliferative lupus nephritis.

Condition Intervention Phase
Nephritis, Lupus Drug: leflunomide combined with prednisone Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 3 Study of Leflunomide Combined With Prednisone Treatment of Proliferative Lupus Nephritis as Induction Therapy

Resource links provided by NLM:

Further study details as provided by Peking University:

Primary Outcome Measures:
  • complete remission of renal disease at 6 months

Secondary Outcome Measures:
  • partial remission at 6 months and adverse events

Study Start Date: October 2002

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients were diagnosed as SLE according to the updated criteria of American College of Rheumatology in 1997, had a systemic lupus erythematosus disease activity index (SLEDAI)equal or greater than 8; had evident renal diseases and biopsy-documented diffuse proliferative or focal proliferative lupus nephritis, with or without coincident membranous nephropathy, and pathological activity index (AI)equal or greater than 4

Exclusion Criteria:

  • Patients who had received cyclophosphamide within the previous 3 months, cerebral lupus, severe infection, liver disease, pregnancy, and anticipated poor compliance with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00268567

Renal Division, Peking University First Hospital
Beijing, China, 100034
Department of Nephrology, Kidney Center and key Lab of PLA, Chinese General Hospital of PLA
Beijing, China
Division of Nephrology, Nanfang Hospital, Southern Medical University
Guangzhou, China
Renal Division, the First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Department of Rheumatology, the Second Affiliated Hospital, Harbin Medical University
Harbin, China
Department of Nephrology, Shanghai Changzheng Hospital
Shanghai, China
Renal Division, Huashan Hospital, Fudan University
Shanghai, China
Renal Division, Renji Hospital, Shanghai Jiaotong University
Shanghai, China
Sponsors and Collaborators
Peking University
Principal Investigator: Haiyan Wang, M.D. Institute of Nephrology, Peking University
  More Information Identifier: NCT00268567     History of Changes
Other Study ID Numbers: CLLNT-2002HL0133
Study First Received: December 21, 2005
Last Updated: December 21, 2005

Additional relevant MeSH terms:
Lupus Nephritis
Kidney Diseases
Urologic Diseases
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents processed this record on September 20, 2017